Abstract
The natural history of neovascular age-related macular degeneration (nAMD) leads to scarring and loss of vision. Since the advent of anti-VEGF therapies, which are very effective for controlling exudation, large disciform scars are rarely encountered in the clinic. However long term studies show that smaller and less severe fibrotic scars are not uncommon and develop over time despite optimal treatment. This means that additional mechanisms of action may be required to completely address this condition. To permit new treatments, a proper understanding of the clinical impact of fibrosis is required. This review is focused on clinical aspects of fibrosis and summarises recent data on biomarkers, prevalence, causes, consequences, and therapies, highlighting the most important and urgent topics to tackle in order to advance in the treatment of fibrosis.
| Original language | English |
|---|---|
| Number of pages | 9 |
| Journal | Eye |
| Early online date | 28 Aug 2024 |
| DOIs | |
| Publication status | Early online date - 28 Aug 2024 |
Keywords
- Fibrosis
- age-related
- neovascular macular degeneration
- anti-VEGF era
ASJC Scopus subject areas
- Ophthalmology
- Sensory Systems
Fingerprint
Dive into the research topics of 'Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver